Sosei Heptares’ COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development
The Pharma Data
NOVEMBER 19, 2020
20, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19. Zhang, et al, Science (2020) DOI: 10.1126/science.abb3405. References.
40 
Let's personalize your content